Yizhi Liu Awarded the “He's Innovation Award in Ophthalmology” by CCOS
Reported by Jiawei Wang
Edited by Xianjing Wei
The 23rd Congress of Chinese Ophthalmological Society (CCOS) was successfully held in Hangzhou, China, September 12-16, 2018. CCOS, the biggest and most important ophthalmic meeting in China. The meeting covered all aspects of ophthalmology and visual science, as well as advances in world up-to-date clinical and basic research. Besides the traditional highlights such as Plenary Session, Subspecialty and Multi-discipline Session, Video Symposium, Live Surgery etc., the Belt and Road Forum, COS-AAO Chapter in China Forum and Mainland, Taiwan, Hong Kong and Macao Ophthalmology Forum also brought audience an impressive academic journey. More than 10,000 delegates attended the congress. Besides, up to 700 top international and domestic invited speakers gave speeches for the dynamic scientific programs on the development of new technology, up-to-date knowledge and experience in ophthalmology.
On the congress, Professor Yizhi Liu, the director of Zhongshan Ophthalmic Center, Sun Yat-sen University and the State Key Laboratory of Ophthalmology has been awarded the “He’s Innovation Award in Ophthalmology” by CCOS.
Professor Yizhi Liu of Zhongshan Ophthalmic Center, Sun Yat-sen University, discovered lens epithelial stem cells (LECs) with his international team after 18 years of research, demonstrating that BMI-1 and Pax6 are essential factors for the maintenance and self-renewal of LECs. To attain tissue repair and regeneration with stem cells, he established a new minimally invasive surgery method that preserves endogenous LECs and their natural environment, and regenerates lens with gain of visual function. The treatment achieves functional in situ lens regeneration in human for the first time, and has been successfully applied to pediatric cataract in clinic. This prominent research was published in Nature (2016,531:323-8) and ranked as one of the eight Notable Advances in 2016 by Nature Medicine.
Professor Yizhi Liu, the chief scientist of 973 Program and the leader of Innovative Research Groups of National Natural Science Foundation of China (NSFC), currently serves as the director of State Key Laboratory of Ophthalmology and Zhongshan Ophthalmic Center, Sun Yat-sen University. He is a pioneer to promote the torsional mode of phacoemulsification globally, and published reviews and clinical criteria in Science, NEJM and the Lancet. He developed a novel surgical method that achieves functional in situ lens regeneration in human for the first time, and has been successfully applied to the clinical treatment of pediatric cataract. This prominent research was published in Nature and ranked as one of the eight Notable Advances in 2016 by Nature Medicine.